In addition, overexpression of SMYD2 has been observed in hepatocellular carcinoma (HCC) [56, 57], gastric cancer [58], pancreatic ductal adenocarcinoma (PDAC) [59], papillary thyroid carcinoma [60], and colon cancer [61]. This evidence concerns the gene SMYD2 and hepatocellular carcinoma.